Biomarkers in newborns with hypoxic-ischemic encephalopathy treated with therapeutic hypothermia

Michniewicz, Barbara; Szpecht, Dawid; Sowińska, Anna; Sibiak, Rafał; Szymankiewicz, Marta; Gadzinowski, Janusz

doi:10.1007/s00381-020-04645-z

Cited by 26 publications

(21 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Hypoxic-ischemic encephalopathy can result in severe neurodevelopmental disability and mortality in, respectively, 24.9% and 34.1% of cases [ 13 ]. Further observations of infants suffering from perinatal asphyxia showed that 27–33% of them aged 6–7 years will have features of intellectual disability [ 14 ]. This brain damage is secondary to an episode of hypoxia-ischemia as well as reoxygenation-reperfusion following resuscitation [ 15 ].…”

Section: Introductionmentioning

confidence: 99%

Alzheimer’s Disease Associated Presenilin 1 and 2 Genes Dysregulation in Neonatal Lymphocytes Following Perinatal Asphyxia

Tarkowska

Furmaga-Jabłońska

Bogucki

et al. 2021

IJMS

View full text Add to dashboard Cite

Perinatal asphyxia is mainly a brain disease leading to the development of neurodegeneration, in which a number of peripheral lesions have been identified; however, little is known about the expression of key genes involved in amyloid production by peripheral cells, such as lymphocytes, during the development of hypoxic-ischemic encephalopathy. We analyzed the gene expression of the amyloid protein precursor, β-secretase, presenilin 1 and 2 and hypoxia-inducible factor 1-α by RT-PCR in the lymphocytes of post-asphyxia and control neonates. In all examined periods after asphyxia, decreased expression of the genes of the amyloid protein precursor, β-secretase and hypoxia-inducible factor 1-α was noted in lymphocytes. Conversely, expression of presenilin 1 and 2 genes decreased on days 1–7 and 8–14 but increased after survival for more than 15 days. We believe that the expression of presenilin genes in lymphocytes could be a potential biomarker to determine the severity of the post-asphyxia neurodegeneration or to identify the underlying factors for brain neurodegeneration and get information about the time they occurred. This appears to be the first worldwide data on the role of the presenilin 1 and 2 genes associated with Alzheimer’s disease in the dysregulation of neonatal lymphocytes after perinatal asphyxia.

show abstract

Section: Introductionmentioning

confidence: 99%

Alzheimer’s Disease Associated Presenilin 1 and 2 Genes Dysregulation in Neonatal Lymphocytes Following Perinatal Asphyxia

Tarkowska

Furmaga-Jabłońska

Bogucki

et al. 2021

IJMS

View full text Add to dashboard Cite

show abstract

“…Reports of biomarkers being correlated with MRI-indicated lesions are limited. Lactate may be beneficial for predicting severe MRI-indicated lesions that are typically correlated with poor neurodevelopmental outcomes at 1 year old [ 15 , 27 ]. Neurodevelopmental outcomes at 1 year old are closely related to the two weeks of MRI findings after birth for neonatal patients with stage II and stage III HIE [ 28 , 29 ].…”

Section: Discussionmentioning

confidence: 99%

Identifying Early Diagnostic Biomarkers Associated with Neonatal Hypoxic-Ischemic Encephalopathy

et al. 2021

View full text Add to dashboard Cite

Background: Identifying an effective method for the early diagnosis of neonatal hypoxic-ischemic encephalopathy (HIE) would be beneficial for effective therapies. Methods: We studied blood biomarkers before 6 h after birth to correlate the degree of neonatal HIE. A total of 80 patients were divided into group 1 (mild HIE) and group 2 (moderate or severe HIE). Then, 42 patients from group 2 received hypothermia therapy and were further divided into group 3 (unremarkable or mild MRI results) and group 4 (severe MRI results). Results: Between groups 1 and 2, lactate, creatinine, white blood cells, and lactate dehydrogenase (LDH) were significantly different. Between groups 3 and 4, lactate, prothrombin time, and albumin were significantly different. Sarnat staging was based on our observation that more than 45 mg/dL of lactate combined with more than 1000 U/L of LDH yielded the highest positive predictive value (PPV) (95.7%; odds ratio, 22.00), but a low negative predictive value (NPV) for moderate or severe HIE. Using more than 45 mg/dL of lactate yielded the highest NPV (71.4%) correlated with moderate or severe HIE. Conclusions: Lactate combined with LDH before 6 h after birth yielded a high PPV. Using combined biomarkers to exclude mild HIE, include moderate or severe HIE, and initialize hypothermia therapy is feasible.

show abstract

“…DIC in the neonate, most commonly occurs in the setting of perinatal asphyxia, but can be due to sepsis and perinatal acquired infections, respiratory distress syndrome and meconium aspiration ( 14 , 137 , 138 ). Severe perinatal asphyxia can cause significant hypoxic brain injury and multi-organ failure, including hepatic damage ( 139 , 140 ). Hypoxic hepatic damage can lead to reduced production of coagulation factors and hypofibrinogenemia ( 140 ).…”

Section: Neonates and Hypofibrinogenemiamentioning

confidence: 99%

Pediatric Fibrinogen PART II—Overview of Indications for Fibrinogen Use in Critically Ill Children

Crighton

Huisman

2021

Front. Pediatr.

View full text Add to dashboard Cite

Bleeding is frequently seen in critically ill children and is associated with increased morbidity and mortality. Fibrinogen is an essential coagulation factor for hemostasis and hypofibrinogenemia is an important risk factor for bleeding in pediatric and adult settings. Cryoprecipitate and fibrinogen concentrate are often given to critically ill children to prevent bleeding and improve fibrinogen levels, especially in the setting of surgery, trauma, leukemia, disseminated intravascular coagulopathy, and liver failure. The theoretical benefit of fibrinogen supplementation to treat hypofibrinogenemia appears obvious, yet the evidence to support fibrinogen supplementation in children is sparce and clinical indications are poorly defined. In addition, it is unknown what the optimal fibrinogen replacement product is in children and neonates or what the targets of treatment should be. As a result, there is considerable variability in practice. In this article we will review the current pediatric and applicable adult literature with regard to the use of fibrinogen replacement in different pediatric critical care contexts. We will discuss the clinical indications for fibrinogen supplementation in critically ill children and the evidence to support their use. We summarize by highlighting current knowledge gaps and areas for future research.

show abstract

Biomarkers in newborns with hypoxic-ischemic encephalopathy treated with therapeutic hypothermia

Cited by 26 publications

References 48 publications

Alzheimer’s Disease Associated Presenilin 1 and 2 Genes Dysregulation in Neonatal Lymphocytes Following Perinatal Asphyxia

Alzheimer’s Disease Associated Presenilin 1 and 2 Genes Dysregulation in Neonatal Lymphocytes Following Perinatal Asphyxia

Identifying Early Diagnostic Biomarkers Associated with Neonatal Hypoxic-Ischemic Encephalopathy

Pediatric Fibrinogen PART II—Overview of Indications for Fibrinogen Use in Critically Ill Children

Contact Info

Product

Resources

About